Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from Enbrel to Benepali in rheumatic disease
NL-OMON21708Active, not recruiting
- Sponsor
- Sint Maartenskliniek
- Start
- Jun 2016
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of etanercept in rheumatism, rheumatoid arthritis (RA), psoriatic arthritis (PsA) and 1 more (2 cohorts), sponsored by Sint Maartenskliniek. Primary endpoint: 6-month treatment persistence. Started Jun 2016; status: active, not recruiting.
02
Drugs
etanercept
03
Conditions
rheumatismrheumatoid arthritis (RA)psoriatic arthritis (PsA)spondyloarthritis (SpA)
Beyond the preview
Go deeper on NL-OMON21708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21708.